Atlas Trials

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Clinical trial NCT00702403 · COMPLETED

Trial details

NCT number
NCT00702403
Sponsor
Fred Hutchinson Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic Phase Chronic Myelogenous LeukemiaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaPhiladelphia Positive Adult Acute Lymphoblastic LeukemiaPhiladelphia Positive Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRelapsing Chronic Myelogenous Leukemia
Start date
2008-08-14
Primary completion
2013-12-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.